Michael M. Frank
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Michael M. Frank has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Haixiang Jiang
Duke University Medical Center
6 shared publications- Bruce L. Zuraw
Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, Calif
2 shared publications David C. Montefiori
Duke University Medical Center
2 shared publicationsEric Wagner
Department of Pediatrics, Duke University Medical Center, Durham, NC 27710
2 shared publicationsLarry Liao
Duke University Medical Center
2 shared publicationsAleena Banerji
Massachusetts General Hospital, Boston, Massachusetts
1 shared publication
Latest Publications
- 1 November 2016
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 138 (5) , e20160575
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency
Hereditary angioedema (HAE) is a potentially life-threatening inherited disease characterized by attacks of skin swelling, severe abdominal pain, and upper airway swelling. Attacks typically begin in childhood, but the appropriate diagnosis is often missed. Attacks do not respond to epinephrine, antihistamines, or glucocorticoids. Recently, many effective drugs have been approved for treatment of adults with HAE, and the Medical Advisory Board of the HAE Patient’s Association has developed and reported treatment recommendations for adults. Only 1 medication is approved for treatment of children <12 years of age, and there are no reported consensus recommendations for treatment of young children in the United States. The 11-member Medical Advisory Board, with extensive experience in the treatment of children, in concert with the leaders of the HAE Patient’s Association, has developed these consensus recommendations to help in recognition, diagnosis, treatment of attacks, and prophylaxis of children with HAE.
- 1 November 2016
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 138 (5) , e20160575
Management of Children With Hereditary Angioedema Due to C1 Inhibitor Deficiency
Hereditary angioedema (HAE) is a potentially life-threatening inherited disease characterized by attacks of skin swelling, severe abdominal pain, and upper airway swelling. Attacks typically begin in childhood, but the appropriate diagnosis is often missed. Attacks do not respond to epinephrine, antihistamines, or glucocorticoids. Recently, many effective drugs have been approved for treatment of adults with HAE, and the Medical Advisory Board of the HAE Patient’s Association has developed and reported treatment recommendations for adults. Only 1 medication is approved for treatment of children <12 years of age, and there are no reported consensus recommendations for treatment of young children in the United States. The 11-member Medical Advisory Board, with extensive experience in the treatment of children, in concert with the leaders of the HAE Patient’s Association, has developed these consensus recommendations to help in recognition, diagnosis, treatment of attacks, and prophylaxis of children with HAE.
- 1 November 2013
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 33 (4) , 495-503
Update on Preventive Therapy (Prophylaxis) for Hereditary Angioedema
- 1 November 2013
- Published by Elsevier in Immunology and Allergy Clinics of North America
- Vol. 33 (4) , 495-503
Update on Preventive Therapy (Prophylaxis) for Hereditary Angioedema
- 12 January 2011
- Published by Springer Nature in Immunologic Research
- Vol. 49 (1-3) , 159
Erratum to: Mechanisms by which HIV envelope minimizes immunogenicity
- 12 January 2011
- Published by Springer Nature in Immunologic Research
- Vol. 49 (1-3) , 159
Erratum to: Mechanisms by which HIV envelope minimizes immunogenicity
- 1 January 2011
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 32 (1) , 17-21
Update on preventive therapy (prophylaxis) of hereditary angioedema
The prophylaxis of patients with hereditary angioedema to prevent attacks has gone through major revision as new agents for prophylaxis have come on the market. Earlier treatments, developed empirically, included the fibinolysis inhibitors epsilon aminocaproic acid and tranexamic acid and attenuated androgens such as danazol. With the development of these agents, many patients had relief of severe symptoms, and drugs in these classes have been the only treatments available in America. Their major disadvantage has been their side effects, which range from minor to severe. In Europe various products containing C1 inhibitor, the serum protein deficient in this disease, were prepared from pooled donor plasma. They were reported to be effective in ending attacks and in prophylaxis, but these products in general were not used in prophylaxis, in part because of the short half life of the plasma protein. One such product, C1 esterase inhibitor, has now been shown in a rigorous double-blind study to be effective in prevention of hereditary angioedema attacks and has been approved by the US Federal Drug Administration for prophylaxis of the disease. Its use has been attended by few side-effects, reflecting the fact that it is the purified naturally circulating product.
- 1 January 2011
- Published by Oceanside Publications Inc. in Allergy and Asthma Proceedings
- Vol. 32 (1) , 17-21
Update on preventive therapy (prophylaxis) of hereditary angioedema
The prophylaxis of patients with hereditary angioedema to prevent attacks has gone through major revision as new agents for prophylaxis have come on the market. Earlier treatments, developed empirically, included the fibinolysis inhibitors epsilon aminocaproic acid and tranexamic acid and attenuated androgens such as danazol. With the development of these agents, many patients had relief of severe symptoms, and drugs in these classes have been the only treatments available in America. Their major disadvantage has been their side effects, which range from minor to severe. In Europe various products containing C1 inhibitor, the serum protein deficient in this disease, were prepared from pooled donor plasma. They were reported to be effective in ending attacks and in prophylaxis, but these products in general were not used in prophylaxis, in part because of the short half life of the plasma protein. One such product, C1 esterase inhibitor, has now been shown in a rigorous double-blind study to be effective in prevention of hereditary angioedema attacks and has been approved by the US Federal Drug Administration for prophylaxis of the disease. Its use has been attended by few side-effects, reflecting the fact that it is the purified naturally circulating product.
- 14 December 2010
- Published by Springer Nature in Immunologic Research
- Vol. 49 (1-3) , 147-158
Mechanisms by which HIV envelope minimizes immunogenicity
With many viruses, vaccines containing the appropriate envelope antigens have provided strong and long lasting immunity. Not so with HIV-1 envelope, despite two decades of experience with various envelope and core constituent vaccines, protection provided has been weak or absent. Our laboratory has been systematically investigating the characteristics of HIV-1 envelope gp140, the principle HIV-1 envelope protein heterodimer responsible for HIV infectivity. We have identified two properties of HIV-1 envelope gp140 that may be important factors in reducing immunogenicity. HIV envelope protein gp140 rejects complement binding. Such binding can be of vital importance, since an extensive literature suggests that complement binding markedly increases immunogenicity, and, more importantly, complement binding influences the type of immune response. For many antigens, C3 binding is required for normal transport of antigens into follicles to initiate a normal germinal center response, and in the absence of appropriate complement binding, the antibody response is reduced, short lived with short-lived memory cell formation, and for an unknown reason, the antibody response shows increased affinity maturation of antibody. These features are characteristic of the HIV-1 antibody response. Just as important is the finding that envelope gp140 is highly unstable on injection, is rapidly removed from the circulation, and is degraded into peptides. This short-lived antigen may be available on initial exposure to the immune system for too short a period of time, particularly in the absence of complement binding, to be an adequate immunogen.
- 14 December 2010
- Published by Springer Nature in Immunologic Research
- Vol. 49 (1-3) , 147-158
Mechanisms by which HIV envelope minimizes immunogenicity
With many viruses, vaccines containing the appropriate envelope antigens have provided strong and long lasting immunity. Not so with HIV-1 envelope, despite two decades of experience with various envelope and core constituent vaccines, protection provided has been weak or absent. Our laboratory has been systematically investigating the characteristics of HIV-1 envelope gp140, the principle HIV-1 envelope protein heterodimer responsible for HIV infectivity. We have identified two properties of HIV-1 envelope gp140 that may be important factors in reducing immunogenicity. HIV envelope protein gp140 rejects complement binding. Such binding can be of vital importance, since an extensive literature suggests that complement binding markedly increases immunogenicity, and, more importantly, complement binding influences the type of immune response. For many antigens, C3 binding is required for normal transport of antigens into follicles to initiate a normal germinal center response, and in the absence of appropriate complement binding, the antibody response is reduced, short lived with short-lived memory cell formation, and for an unknown reason, the antibody response shows increased affinity maturation of antibody. These features are characteristic of the HIV-1 antibody response. Just as important is the finding that envelope gp140 is highly unstable on injection, is rapidly removed from the circulation, and is degraded into peptides. This short-lived antigen may be available on initial exposure to the immune system for too short a period of time, particularly in the absence of complement binding, to be an adequate immunogen.
- 1 December 2010
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 11 (6) , 383-388
An Overview of Novel Therapies for Acute Hereditary Angioedema
Hereditary angioedema is an episodic swelling disorder with autosomal dominant inheritance. Attacks are characterized by nonpitting edema of external or mucosal body surfaces. Patients often present with swelling of the extremities, abdominal pain, and swelling of the mouth and throat, which can at times lead to asphyxiation. The disease is caused by a mutation in the gene encoding the complement C1-inhibitor protein, which leads to unregulated production of bradykinin.
- 1 December 2010
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 11 (6) , 383-388
An Overview of Novel Therapies for Acute Hereditary Angioedema
Hereditary angioedema is an episodic swelling disorder with autosomal dominant inheritance. Attacks are characterized by nonpitting edema of external or mucosal body surfaces. Patients often present with swelling of the extremities, abdominal pain, and swelling of the mouth and throat, which can at times lead to asphyxiation. The disease is caused by a mutation in the gene encoding the complement C1-inhibitor protein, which leads to unregulated production of bradykinin.
- 31 August 2010
- Published by Elsevier in Molecular Immunology
- Vol. 47 (13) , 2231
The classical and alternative complement pathways play different roles in the immune response
- 31 August 2010
- Published by Elsevier in Molecular Immunology
- Vol. 47 (13) , 2231
The classical and alternative complement pathways play different roles in the immune response
- Top Cited PapersOpen Access
- 28 July 2010
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 6 (1) , 24
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. To update the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (circa 2010). The Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May 15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed at the meeting and then circulated for review. This manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema that resulted from that conference. Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical trials and then evidence-based guidelines and standards for HAE disease management.
- 28 July 2010
- Published by Springer Nature in Allergy, Asthma & Clinical Immunology
- Vol. 6 (1) , 24
Top Cited PapersOpen Access2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema
We published the Canadian 2003 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema (HAE; C1 inhibitor [C1-INH] deficiency) and updated this as Hereditary angioedema: a current state-of-the-art review: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema. To update the International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema (circa 2010). The Canadian Hereditary Angioedema Network (CHAEN)/Réseau Canadien d'angioédème héréditaire (RCAH) http://www.haecanada.com and cosponsors University of Calgary and the Canadian Society of Allergy and Clinical Immunology (with an unrestricted educational grant from CSL Behring) held our third Conference May 15th to 16th, 2010 in Toronto Canada to update our consensus approach. The Consensus document was reviewed at the meeting and then circulated for review. This manuscript is the 2010 International Consensus Algorithm for the Diagnosis, Therapy and Management of Hereditary Angioedema that resulted from that conference. Consensus approach is only an interim guide to a complex disorder such as HAE and should be replaced as soon as possible with large phase III and IV clinical trials, meta analyses, and using data base registry validation of approaches including quality of life and cost benefit analyses, followed by large head-to-head clinical trials and then evidence-based guidelines and standards for HAE disease management.
- 1 February 2010
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (2) , S262-S271
Complement disorders and hereditary angioedema
- 1 February 2010
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 125 (2) , S262-S271
Complement disorders and hereditary angioedema
- Open Access
- 1 January 2010
- Published by Elsevier in World Allergy Organization Journal
- Vol. 3 (3) , S29-S33
Recombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema
- 1 January 2010
- Published by Elsevier in World Allergy Organization Journal
- Vol. 3 (3) , S29-S33
Open AccessRecombinant and Plasma-Purified Human C1 Inhibitor for the Treatment of Hereditary Angioedema